These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35790835)

  • 1. Personalized treatment supported by automated quantitative fluid analysis in active neovascular age-related macular degeneration (nAMD)-a phase III, prospective, multicentre, randomized study: design and methods.
    Coulibaly LM; Sacu S; Fuchs P; Bogunovic H; Faustmann G; Unterrainer C; Reiter GS; Schmidt-Erfurth U
    Eye (Lond); 2023 May; 37(7):1464-1469. PubMed ID: 35790835
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of sub-retinal fluid in determining treatment outcomes in patients with neovascular age-related macular degeneration--a phase IV randomised clinical trial with ranibizumab: the FLUID study.
    Arnold JJ; Markey CM; Kurstjens NP; Guymer RH
    BMC Ophthalmol; 2016 Mar; 16():31. PubMed ID: 27009515
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Artificial intelligence-based fluid quantification and associated visual outcomes in a real-world, multicentre neovascular age-related macular degeneration national database.
    Martin-Pinardel R; Izquierdo-Serra J; De Zanet S; Parrado-Carrillo A; Garay-Aramburu G; Puzo M; Arruabarrena C; Sararols L; Abraldes M; Broc L; Escobar-Barranco JJ; Figueroa M; Zapata MA; Ruiz-Moreno JM; Moll-Udina A; Bernal-Morales C; Alforja S; Figueras-Roca M; Gómez-Baldó L; Ciller C; Apostolopoulos S; Mosinska A; Casaroli Marano RP; Zarranz-Ventura J;
    Br J Ophthalmol; 2024 Jan; 108(2):253-262. PubMed ID: 36627173
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Residual Retinal Fluid on Visual Function in Ranibizumab-Treated Neovascular Age-Related Macular Degeneration.
    Holekamp NM; Sadda S; Sarraf D; Guymer R; Hill L; Blotner S; Spicer G; Gune S
    Am J Ophthalmol; 2022 Jan; 233():8-17. PubMed ID: 34289338
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Application of Automated Quantification of Fluid Volumes to Anti-VEGF Therapy of Neovascular Age-Related Macular Degeneration.
    Schmidt-Erfurth U; Vogl WD; Jampol LM; Bogunović H
    Ophthalmology; 2020 Sep; 127(9):1211-1219. PubMed ID: 32327254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. VALIDATION OF AN AUTOMATED FLUID ALGORITHM ON REAL-WORLD DATA OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION OVER FIVE YEARS.
    Gerendas BS; Sadeghipour A; Michl M; Goldbach F; Mylonas G; Gruber A; Alten T; Leingang O; Sacu S; Bogunovic H; Schmidt-Erfurth U
    Retina; 2022 Sep; 42(9):1673-1682. PubMed ID: 35994584
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of intraretinal and subretinal fluid on clinical and anatomical outcomes in patients with neovascular age-related macular degeneration treated with bimonthly, treat-and-extend and as-needed ranibizumab in the In-Eye study.
    Saenz-de-Viteri M; Recalde S; Fernandez-Robredo P; López Gálvez MI; Arias Barquet L; Figueroa MS; García-Arumí J; García-Layana A;
    Acta Ophthalmol; 2021 Dec; 99(8):861-870. PubMed ID: 33720541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tolerating Subretinal Fluid in Neovascular Age-Related Macular Degeneration Treated with Ranibizumab Using a Treat-and-Extend Regimen: FLUID Study 24-Month Results.
    Guymer RH; Markey CM; McAllister IL; Gillies MC; Hunyor AP; Arnold JJ;
    Ophthalmology; 2019 May; 126(5):723-734. PubMed ID: 30502372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationship between retinal fluid characteristics and vision in neovascular age-related macular degeneration: HARBOR post hoc analysis.
    Sadda S; Holekamp NM; Sarraf D; Ebraheem A; Fan W; Hill L; Blotner S; Spicer G; Gune S
    Graefes Arch Clin Exp Ophthalmol; 2022 Dec; 260(12):3781-3789. PubMed ID: 35687173
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Automated quantification of macular fluid in retinal diseases and their response to anti-VEGF therapy.
    Michl M; Fabianska M; Seeböck P; Sadeghipour A; Haj Najeeb B; Bogunovic H; Schmidt-Erfurth UM; Gerendas BS
    Br J Ophthalmol; 2022 Jan; 106(1):113-120. PubMed ID: 33087314
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Intra- and Subretinal Fluid on Vision Based on Volume Quantification in the HARBOR Trial.
    Riedl S; Vogl WD; Waldstein SM; Schmidt-Erfurth U; Bogunović H
    Ophthalmol Retina; 2022 Apr; 6(4):291-297. PubMed ID: 34922038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of an Artificial Intelligence-Based Detector of Sub- and Intraretinal Fluid on a Large Set of Optical Coherence Tomography Volumes in Age-Related Macular Degeneration and Diabetic Macular Edema.
    Habra O; Gallardo M; Meyer Zu Westram T; De Zanet S; Jaggi D; Zinkernagel M; Wolf S; Sznitman R
    Ophthalmologica; 2022; 245(6):516-527. PubMed ID: 36215958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Macular morphology and visual acuity in the comparison of age-related macular degeneration treatments trials.
    Jaffe GJ; Martin DF; Toth CA; Daniel E; Maguire MG; Ying GS; Grunwald JE; Huang J;
    Ophthalmology; 2013 Sep; 120(9):1860-70. PubMed ID: 23642377
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A paradigm shift in imaging biomarkers in neovascular age-related macular degeneration.
    Schmidt-Erfurth U; Waldstein SM
    Prog Retin Eye Res; 2016 Jan; 50():1-24. PubMed ID: 26307399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
    Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
    Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration.
    Simader C; Ritter M; Bolz M; Deák GG; Mayr-Sponer U; Golbaz I; Kundi M; Schmidt-Erfurth UM
    Ophthalmology; 2014 Jun; 121(6):1237-45. PubMed ID: 24684838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study).
    Fung AT; Kumar N; Vance SK; Slakter JS; Klancnik JM; Spaide RS; Freund KB
    Eye (Lond); 2012 Sep; 26(9):1181-7. PubMed ID: 22878451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-VEGF-resistant subretinal fluid is associated with better vision and reduced risk of macular atrophy.
    Zarbin MA; Hill L; Maunz A; Gliem M; Stoilov I
    Br J Ophthalmol; 2022 Nov; 106(11):1561-1566. PubMed ID: 34039560
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Subretinal Fluid Resolution and Visual Acuity in Patients with Neovascular Age-Related Macular Degeneration: A HARBOR Post Hoc Analysis.
    Lally DR; Hill L; Amador-Patarroyo MJ
    Ophthalmol Retina; 2022 Nov; 6(11):1054-1060. PubMed ID: 35654363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative assessment of retinal fluid in neovascular age-related macular degeneration under anti-VEGF therapy.
    Reiter GS; Schmidt-Erfurth U
    Ther Adv Ophthalmol; 2022; 14():25158414221083363. PubMed ID: 35340749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.